Cytosorbents Corporation (NASDAQ:CTSO) Stock Position Increased by Skylands Capital LLC

Skylands Capital LLC lifted its holdings in Cytosorbents Corporation (NASDAQ:CTSO - Free Report) by 7.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 3,002,702 shares of the medical research company's stock after buying an additional 221,080 shares during the quarter. Skylands Capital LLC owned approximately 4.80% of Cytosorbents worth $3,003,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC boosted its position in Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after purchasing an additional 8,400 shares during the period. Northern Trust Corp lifted its stake in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after buying an additional 16,701 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Cytosorbents during the fourth quarter valued at $30,000. Key Client Fiduciary Advisors LLC grew its position in shares of Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after acquiring an additional 43,900 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents in the 4th quarter worth about $99,000. 32.87% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on CTSO. Wall Street Zen began coverage on shares of Cytosorbents in a research note on Wednesday, May 21st. They set a "hold" rating for the company. D. Boral Capital reiterated a "buy" rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Wednesday, June 25th. Finally, HC Wainwright reissued a "neutral" rating and issued a $1.00 price objective on shares of Cytosorbents in a report on Thursday, May 15th.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO traded down $0.29 during midday trading on Wednesday, reaching $1.00. 573,728 shares of the company traded hands, compared to its average volume of 150,287. The company has a market cap of $62.61 million, a price-to-earnings ratio of -3.57 and a beta of 1.18. The stock has a 50-day moving average price of $1.01 and a 200 day moving average price of $1.02. Cytosorbents Corporation has a 52 week low of $0.71 and a 52 week high of $1.61. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.61 and a quick ratio of 2.30.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.01 million. Cytosorbents had a negative net margin of 41.77% and a negative return on equity of 105.04%. Sell-side analysts anticipate that Cytosorbents Corporation will post -0.3 earnings per share for the current fiscal year.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.